Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.
Psychotropic medicines in pregnancy and breastfeeding
Psychiatry · UK scope · Sources checked 27 Aug 2026 · Clinical review pending
!
Toxicity, severe relapse or hazardous withdrawal
Suicidality, mania, psychosis, severe self-neglect, serotonin toxicity, lithium toxicity, major oversedation, respiratory compromise or seizures after a treatment change requires urgent clinical assessment rather than remote reassurance about reproductive risk.
Action: Stabilise immediate physical and psychiatric risk, record every medicine and the timing of last doses, assess pregnancy or infant context, obtain targeted observations and tests, and contact emergency, toxicology, obstetric, neonatal and specialist perinatal mental-health services according to the active problem; do not advise abrupt blanket cessation.
Purpose and principles
Make defensible, person-centred psychotropic decisions through conception, pregnancy, birth and breastfeeding by separating illness risk from medicine exposure, using indication-specific evidence, planning neonatal observation and preserving effective treatment when clinically necessary.
Psychotropic prescribing in the perinatal period is a sequence of indication-specific decisions, not a league table of supposedly safe and unsafe drugs. The comparison includes at least four pathways: continuing effective treatment, reducing or stopping, switching, and leaving illness untreated or undertreated. Each has time-dependent consequences. A small uncertain fetal signal may be less important than a predictable recurrence of psychosis with loss of nutrition, antenatal attendance or safety; in another person, an ineffective medicine with avoidable exposure has no defensible role.
Begin with diagnosis and evidence of benefit. Reconstruct the target symptoms, severity, previous admissions, suicide or self-neglect, postpartum history, response latency, adverse effects and relapse after missed doses. Confirm current dose and adherence from prescription, patient and pharmacy records. Ask about non-prescribed medicines, herbal products, alcohol, nicotine and drugs. Establish gestation or pregnancy intention and discuss feeding as a preference that can change, not as a condition imposed before treatment is offered.
Practice
Two practice questions
Your practice draft is saved in this browser.
Question 1 of 2
0 correct
PsychiatryOriginal SBA
Established SSRI and breastfeeding
A full-term healthy newborn is breastfeeding, and the parent remained well throughout pregnancy on an effective SSRI that is not the usual preferred new breastfeeding choice. What is the best general approach?
Sources and review status7 sources · checked 27 Aug 2026 · clinical review pending+
Sources
Sources and review status
National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.
Quetiapine SmPCLicensed adult bipolar-depression titration and product safety information.
Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. ·
Risk communication should use absolute rather than dramatic relative language. Separate congenital malformation, pregnancy loss, growth, preterm birth, neonatal adaptation and longer-term neurodevelopment because they have different evidence and exposure windows. Explain the background frequency of common outcomes and the weaknesses of observational studies, including confounding by illness severity, smoking, other medicines and ascertainment. Record what matters most to the person and check understanding rather than asking only whether they consent.
NICE prescribing principles support the lowest-risk clinically appropriate drug, use of the lowest effective dose, and a single medicine where possible. The lowest dose is not automatically safest if it creates exposure without controlling illness. Repeated switching can add exposure to several medicines and destabilise someone whose established treatment works. When change is justified, taper or cross-titrate according to withdrawal liability, episode risk and product guidance, allowing enough observation to decide whether the replacement is effective whenever pregnancy timing permits.
Medicine classes require different actions. Antidepressants need discussion of discontinuation, neonatal adaptation, persistent pulmonary hypertension signals and the small postpartum-haemorrhage association with SSRI or SNRI use in the month before delivery. Antipsychotics require metabolic monitoring, and gestational diabetes testing is important because NICE recommends monitoring weight and offering an oral glucose tolerance test in pregnancy. Benzodiazepines are generally not offered except for short-term treatment of severe anxiety or agitation, and gradual withdrawal is considered when planning pregnancy.
Valproate cannot be handled as routine bipolar prescribing. MHRA measures require strict safeguards because of major fetal malformation and neurodevelopmental risks; a woman or girl able to have children must meet Pregnancy Prevention Programme conditions, and initiation in a new patient younger than 55 has two-specialist restrictions unless specified exceptions apply. Pregnancy or pregnancy planning requires urgent specialist review, but patients must not be told simply to stop on their own because sudden recurrence or seizures can also be dangerous.
Breastfeeding decisions depend on maternal dose, pharmacokinetics, infant gestation and health, exposure during pregnancy, combination therapy and the feasibility of observing feeding, arousal, weight and hydration. SPS recommendations for preferred SSRIs and antipsychotics apply to full-term healthy infants. Prematurity, jaundice, illness or multiple sedating drugs warrants specialist pharmacy or paediatric advice. A medicine that was effective through pregnancy may reasonably be continued even if another is preferred in general, avoiding destabilisation and a second exposure.
Before discharge after birth, reconcile the actual regimen and ensure that maternity, mental-health, primary-care and neonatal records agree. NICE calls for a full neonatal assessment after psychotropic exposure in pregnancy, accounting for variable timing of effects and the need for further monitoring after early discharge. Give the family concrete infant warning signs and a contact route without implying that ordinary infant behaviour proves toxicity. Review maternal mental state alongside infant outcomes so concern about transfer does not lead to concealed non-adherence.
Key points
Ask what the medicine treats, whether it works, what happened during previous withdrawal, and which alternatives failed before comparing reproductive safety data.
NICE recommends the lowest-risk suitable medicine, the lowest effective rather than ineffective dose, and monotherapy where possible, while accounting for previous response.
A pregnancy registry signal is not the same as individual causation; explain background outcome rates, absolute increments, evidence limits and illness-related harms in understandable numbers where available.
Do not switch a stable effective antidepressant solely because another drug is generally preferred for breastfeeding; SPS prioritises maternal symptom control and individual infant assessment.
Valproate carries stringent MHRA reproductive restrictions, including Pregnancy Prevention Programme requirements for women and girls able to have children and current initiation safeguards for patients younger than 55.
Lithium needs gestation-specific plasma monitoring, hydration and labour instructions; breastfeeding decisions require specialist advice because NICE advises avoidance and SPS describes only closely supervised selected use.
For a full-term healthy breastfed infant, SPS identifies sertraline or paroxetine as preferred SSRIs and quetiapine or haloperidol as preferred agents within their antipsychotic classes, but previous response remains central.
Indications, selection and cautions
Withdrawal pattern
Dizziness, sensory symptoms, anxiety, insomnia, nausea or flu-like effects after abrupt antidepressant reduction may represent discontinuation rather than immediate illness recurrence.
Relapse pattern
Return of the person's characteristic depressive, manic, psychotic or anxiety syndrome over time points toward loss of treatment protection and requires diagnostic review.
Neonatal adaptation
Jitteriness, altered tone, respiratory difficulty, temperature instability, irritability or feeding problems after late exposure can be transient but still require neonatal assessment.
Infant accumulation
Excess sedation, poor feeding, reduced weight gain, fewer wet nappies or abnormal movements during breastfeeding may indicate exposure, illness or feeding difficulty and needs clinical review.
Lithium toxicity
Worsening tremor, vomiting, diarrhoea, ataxia, confusion or drowsiness in the context of dehydration, renal change or interactions is an urgent toxicity pattern.
Serotonin toxicity
Neuromuscular hyperactivity with autonomic disturbance and altered mental state after serotonergic initiation, escalation or interaction distinguishes a medical emergency from ordinary activation.
Red flags requiring action
A newly positive pregnancy test while taking valproate, lithium or another medicine needing specialist review requires prompt coordinated advice, without unsupervised sudden withdrawal.
Discrepancies must be resolved before attributing symptoms or estimating fetal and infant exposure; dispensing history cannot prove ingestion.
02Individual illness and response history
Why
Determine whether each medicine provides clinically important benefit and what occurred during previous changes.
Interpretation and limitations
Repeated severe relapse after withdrawal raises the cost of switching, whereas uncertain diagnosis or absent benefit supports specialist rationalisation.
03Medicine-specific maternal monitoring
Why
Use plasma levels, renal, thyroid, hepatic, metabolic, blood-count, ECG or blood-pressure checks when indicated by the actual treatment.
Interpretation and limitations
Pregnancy physiology may change concentrations and reference context; tests support dose and safety decisions but do not quantify all reproductive outcomes.
04Obstetric exposure review
Why
Establish gestation, timing of exposure, ultrasound findings, pregnancy complications and delivery plan.
Interpretation and limitations
Treatment approach
01Treatment decisionStart with indication and prior benefitFirst stepA psychotropic medicine is being considered, continued or changed during pregnancy or breastfeeding.+
1Verify diagnosis, severity, previous response, withdrawal history, relapse consequences and all current exposures before discussing reproductive data.
2Compare continuation, optimisation, switching and stopping using absolute outcome information, illness risk, gestational timing and the person's informed priorities.
3Agree the lowest-risk effective strategy, usually limiting polypharmacy where feasible, with a taper or cross-titration schedule and named review date when changing treatment.
02Pregnancy exposureRespond without abrupt cessationPregnancy is discovered while a person is taking a psychotropic with important reproductive considerations.+
1Confirm the pregnancy timeline, medicine and dose, assess current mental state and give clear advice not to make an unsupported sudden change.
Regimens, contraindications and interactions
An established effective SSRI can be continued after individual perinatal review; for a new breastfeeding choice in a full-term healthy infant, SPS identifies sertraline as a preferred SSRI because milk transfer is usually low.
Sertraline for adult major depression
The adult SmPC dose is 50 mg orally once daily; if response is insufficient, increase by 50 mg at intervals of at least one week to a maximum of 200 mg daily, then maintain the lowest effective dose and taper gradually when stopping.
Check bipolar features, bleeding medicines, hyponatraemia and serotonergic interactions. Discuss neonatal adaptation and late-pregnancy haemorrhage information, monitor a breastfed infant for agitation, sleep change, diarrhoea, poor feeding and weight gain, and avoid sudden discontinuation.
Quetiapine may be selected when an antipsychotic is needed and prior response supports it; SPS identifies it as the preferred second-generation antipsychotic during breastfeeding of a full-term healthy infant.
Quetiapine when clinically indicated
Use the licensed oral regimen for the actual diagnosis: for adult bipolar depression the SmPC titration is 50 mg on day 1, 100 mg on day 2, 200 mg on day 3 and 300 mg on day 4, with later adjustment only by the specialist treatment plan.
Monitor sedation, postural hypotension, weight, glucose and lipids, and assess falls or bed-sharing risk. Observe the infant for drowsiness, irritability, poor feeding, constipation, abnormal movement and inadequate weight gain, especially with other sedatives.
Complications, monitoring and follow-up
Set a review interval based on illness severity and the medicine change, with early assessment of activation, withdrawal, suicidality, adherence and functional response after initiation or titration.
Complete the treatment-specific physical schedule, including lithium levels and renal or thyroid tests, antipsychotic metabolic measures, or antidepressant interaction and bleeding review as applicable.
At antenatal reviews confirm that the medicine list, gestation, fetal assessment, birth instructions and responsible prescriber are consistent across maternity, primary-care and mental-health records.
After antenatal exposure, ensure the newborn assessment and observation results reach the postnatal team and that carers know what later-emerging feeding, arousal or respiratory signs warrant help.
During breastfeeding review infant alertness, feeding, urine output, weight gain and development together with maternal symptoms, sleep and any pressure to conceal non-adherence.
Revisit the decision when the illness changes, the infant is premature or unwell, feeding plans change, another sedating medicine is introduced or reliable monitoring cannot be delivered.
Special situations
No exposure is neutral
Untreated illness, withdrawal, switching and ineffective low dosing are exposures too, so a comparison that discusses only congenital medicine risks is incomplete.
Timing changes meaning
Organ formation, late neonatal adaptation and milk transfer concern different periods; one undifferentiated pregnancy-risk label obscures the decision that actually matters.
Preference is conditional
A preferred breastfeeding medicine is a starting point for new prescribing, not a command to replace a uniquely effective established treatment without considering destabilisation.
Infants vary
Prematurity, illness, jaundice, dehydration and combined sedatives can lower clearance or increase vulnerability, making full-term healthy-infant guidance inapplicable without specialist review.
Documentation prevents gaps
Recording who prescribes, who monitors and what happens during labour or infant illness prevents contradictory advice across maternity, psychiatry, primary care and paediatrics.
Common pitfalls
01
Calling a medicine safe or unsafe without specifying outcome, exposure timing, absolute risk or evidence uncertainty.
02
Using the lowest possible dose even when it is ineffective, thereby retaining exposure while allowing illness to recur.
03
Automatically switching a stable medicine at pregnancy recognition or birth without considering withdrawal, prior failure and added multi-drug exposure.
04
Applying breastfeeding recommendations for full-term healthy infants unchanged to premature, jaundiced or medically unwell babies.
05
Discussing milk transfer without addressing maternal sleep, relapse prevention, other sedatives and safer infant sleep.
06
Discharging after late-pregnancy exposure without a newborn assessment, observation plan and named route for delayed concerns.
Tell maternity and neonatal teams about late-pregnancy exposure so the newborn receives a full assessment and monitoring tailored to possible adaptation, withdrawal, toxicity or feeding difficulty.
Sedating medicines, alcohol, smoking, recreational drugs, infant prematurity and bed sharing can combine risk; counselling must cover the whole situation rather than medicine transfer alone.
Document one accountable prescriber, the intended dose, monitoring, planned birth actions, feeding discussion, infant observations and what the patient should do if pregnancy or illness occurs.
Fever, clonus, hyperreflexia, autonomic instability and agitation after serotonergic exposure suggests serotonin toxicity and requires urgent medical assessment.
Vomiting, coarse tremor, ataxia, confusion or drowsiness in a person taking lithium may indicate toxicity, particularly with dehydration or an interacting medicine.
A breastfed infant who is unusually sleepy, feeds poorly, has fewer wet nappies, abnormal tone, tremor or inadequate weight gain needs prompt paediatric and medicines review.
Emergent mania, psychosis, suicidal intent or rapid functional collapse after reducing medication outweighs a routine reproductive-medicines discussion and needs same-day crisis care.
Different outcomes relate to different windows, so cumulative labels such as 'exposed pregnancy' cannot replace a dated timeline.
05Full neonatal assessment
Why
Evaluate adaptation, respiratory status, tone, feeding, hydration, glucose or other targeted concerns after antenatal psychotropic exposure.
Interpretation and limitations
Effects may appear at different times; discharge information must state ongoing observations and escalation signs for carers and community professionals.
A healthy full-term infant on one low-transfer medicine differs from a premature unwell infant exposed to several sedatives, requiring different advice.
2Obtain urgent perinatal psychiatry, obstetric and medicines-in-pregnancy advice proportional to the medicine, with specific urgency for valproate or lithium.
3Document the agreed prescribing, fetal assessment, maternal monitoring, birth communication and postpartum relapse-prevention actions across all involved records.
03Breastfeeding assessmentAssess the parent-infant pairA parent taking psychotropic treatment wishes to breastfeed or is already doing so.+
1Consider how essential and effective the treatment is, infant maturity and health, milk transfer evidence, co-medication, maternal stability and sleep requirements.
2Use an established effective medicine where suitable, applying SPS preference guidance without automatic switching and obtaining specialist advice for lithium, clozapine, prematurity or an unwell infant.
3Tell carers which feeding, arousal, hydration, gastrointestinal and weight signs require review, and assign who monitors the parent and who monitors the infant.
04Birth and dischargeTranslate exposure into observationPsychotropic treatment continues late in pregnancy or will restart immediately after birth.+
1Notify maternity and neonatal teams before delivery of the medicines, doses, last-dose plan, expected adaptation or toxicity issues and feeding intentions.
2Complete the newborn assessment and any medicine-specific observation, testing or treatment without separating parent and infant unnecessarily.
3Reconcile the maternal prescription at discharge and provide postnatal mental-state review, infant monitoring instructions and an urgent contact route in plain language.
Lithium may remain the most effective relapse-prevention treatment for a person with severe bipolar disorder when specialist comparison finds that alternatives have failed or create greater illness risk.
Lithium perinatal treatment
Individualise oral dosing to a correctly timed plasma concentration and clinical response; during pregnancy NICE advises levels every four weeks then weekly from 36 weeks, stopping during labour and checking a plasma level 12 hours after the last dose.
Review renal and thyroid function, hydration and interactions; vomiting, infection, pre-eclampsia and postpartum renal shifts can alter concentrations. NICE advises avoiding breastfeeding, while SPS-supported exceptional use requires specialist maternal levels plus infant lithium, thyroid and renal monitoring.